OncoTherapy Science (30O) Price & Analysis

0 Followers

30O Stock Chart & Stats

€0.11

>-€0.01(-4.03%)

At close: Jan 08 4:00 PM EST

€0.11

>-€0.01(-4.03%)

Day’s Range― - ―

52-Week Range€0.06 - €0.19

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€42.98M

Enterprise Value€5.97B

Total Cash (Recent Filing)€1.23B

Total Debt (Recent Filing)€37.14M

Price to Earnings (P/E)―

Beta0.69

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.03

Shares Outstanding408,243,700

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.68

Price to Book (P/B)3.22

Price to Sales (P/S)8.53

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Stronger EquityZero reported debt and a materially larger equity base provide lasting financial flexibility, lowering fixed financing costs and preserving optionality for funding R&D or clinical programs. Over months this reduces default risk and supports strategic partnerships or non-dilutive funding options.

Focused Oncology R&D ModelA clear, concentrated business model in oncology creates durable specialization in tumor biology and immune approaches. This focus enhances scientific expertise, streamlines R&D prioritization, and improves chances of high-value outcomes or collaborations that can sustain the company over the medium term.

Improving Gross MarginsA material improvement in gross margin suggests better product mix or cost controls that improve unit economics. If sustained, higher gross margins can reduce the gap to profitability and make future scale or commercialization less capital intensive, aiding long-term margin sustainability.

Bears Say

Persistent Cash BurnConsistently negative operating and free cash flows indicate the business consumes cash to operate and advance programs rather than generate it. Over a multi-month horizon this heightens reliance on external financing, increases dilution or covenant risk, and constrains the ability to self-fund clinical programs.

Large Ongoing Net LossesNet losses that remain large relative to revenue imply that current operations are not near break-even. Persisting losses erode retained capital, pressure the balance sheet over time, and make profitable scale harder without significant revenue growth or meaningful cost reduction initiatives.

Volatile And Declining RevenueRevenue volatility and a recent decline reduce predictability of cash flows and complicate planning for R&D and commercialization. Over the coming months this instability increases execution risk, hinders leverage of fixed costs, and raises the probability of requiring additional funding under less favorable terms.

30O FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was €0.06 and its highest was €0.19 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is €42.98M.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 177 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Feb 06, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 408,243,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in DE:30O

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.